Q-omics provides the consensus-scored LINGO2 profile across patient tissues and cancer cell-line models. LINGO2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LINGO2 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, LINGO2 RNA expression shows 14,236 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KIRC, and TGCT as cancer lineages where LINGO2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINGO2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINGO2 survival associations across molecular data types. LINGO2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINGO2 RNA expression–survival associations across cancer types. High LINGO2 expression shows unfavorable associations in BLCA, DLBC, LUAD and UCEC, but favorable associations in UVM and UCS. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for LINGO2 RNA expression.
This table summarizes LINGO2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINGO2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINGO2 shows lower tumor expression in KIRC, THCA, BRCA, KICH and UCEC and higher tumor expression in HNSC. The KIRC box plot shows higher LINGO2 RNA expression in normal versus tumor tissue (log2 FC = −0.740, t-test p < 0.001).
This table shows molecular features associated with LINGO2 in patient tissues and cancer cell lines. In patient samples, LINGO2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, LINGO2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
